the Focus of the Study is Macrophage-induced Chemoresistance in Pancreatic Carcinoma Cells During Chemotherapy. Clinical Trial
Official title:
Impact of Macrophages on De-Novo Chemoresistance of Adenocarcinoma Cells
| Verified date | August 2013 |
| Source | Rambam Health Care Campus |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Israel: Ministry of Health |
| Study type | Interventional |
Macrophages are derived from monocytes recruited to the tumor site and stimulated by
specific chemokines secreted by tumor cells. These tumor associated macrophages (TAMs) have
been postulated as being involved in the progression of cancer.
Based on our preliminary findings and on published data we hypothesized that
macrophage-induced chemoresistance (MIC) can promote survival of pancreatic carcinoma cells
during chemotherapy.
The overall goal of this study is to evaluate the mechanism of MIC in an in-vitro model of
Pancreatic ductal adenocarcinoma (PDA).
methods:
1. The human PDA cell line Panc1 will be grown in suitable conditions.
2. Macrophages will be produced by incubating mononuclear cells from the blood of healthy
donors in medium with M-CSF for 7 days.
3. TAMs will be generated by culturing these macrophages with tumor-culture conditioning
medium (TCCM) of PDA Cells for an additional 72 hours.
4. Human pancreatic cells (PANC1) will be treated with gemcitabine following exposure to
macrophages CM.
5. Cell proliferation will be quantified by light microscopy and by an XTT Cell
Proliferation Assay Kit.
| Status | Not yet recruiting |
| Enrollment | 2 |
| Est. completion date | |
| Est. primary completion date | September 2013 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 18 Years to 40 Years |
| Eligibility |
Inclusion Criteria: - healthy people Exclusion Criteria: - refusal to participate |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Rambam Health Care Campus |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | proliferation and migration of PANC1 cell line in the tested groups. | the macrophages will be isolated from the blood we'll get from the healthy volunteers. the outcome measure is related to the basic research and not clinical so there's no symptom/outcome related to the participants. | one day to get the blood samples, and a year after that to complete the basic research | No |
| Secondary | To determine whether direct cell-to-cell interaction or soluble factors participate in MIC. | a year from obtaining the blood samples | No |